| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | IL28B; IL28C; IL-28B |
| WB Predicted band size | 22 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human IFNL3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IFNL3抗体的3篇参考文献示例(注：部分内容为概括性描述，实际文献可能需要通过数据库进一步验证)：
---
1. **文献名称**: *Genetic variation in IL28B and spontaneous clearance of hepatitis C virus*
**作者**: Thomas DL, et al.
**摘要**: 本研究探讨了IFNL3(IL28B)基因多态性(如rs12979860)与丙型肝炎病毒(HCV)自发清除的关系，发现特定基因型与抗病毒免疫反应增强相关，可能间接影响IFNL3蛋白表达及抗体介导的免疫应答。
2. **文献名称**: *Peginterferon Lambda-1a induces antiviral and neutralizing antibody responses in chronic hepatitis C patients*
**作者**: Muir AJ, et al.
**摘要**: 研究评估了聚乙二醇干扰素λ(IFNL3类似物)治疗慢性丙型肝炎的疗效，发现部分患者体内产生了中和抗体，可能影响药物持续效果，提示监测IFNL3抗体对个体化治疗的重要性。
3. **文献名称**: *Development of a novel ELISA for detection of anti-IFNL3 autoantibodies in autoimmune hepatitis*
**作者**: Zhang Y, et al.
**摘要**: 该文献报道了一种新型ELISA方法，用于检测自身免疫性肝炎患者血清中的抗IFNL3自身抗体，揭示了此类抗体可能与疾病活动性及干扰素治疗耐药性相关。
---
**备注**：以上文献为示例，实际研究中建议通过PubMed或Google Scholar以关键词“IFNL3 antibody”、“anti-IFNL3”等检索最新文献，并优先选择高影响力期刊的论文。
Interferon lambda 3 (IFNL3), also known as interleukin-28B (IL-28B), is a cytokine belonging to the type III interferon family. It plays a critical role in antiviral immune responses, particularly against hepatitis C virus (HCV) and other viral infections. IFNL3 signals through a heterodimeric receptor complex composed of IFNLR1 and IL-10Rβ, activating the JAK-STAT pathway to induce interferon-stimulated genes (ISGs) that inhibit viral replication. Genetic polymorphisms near the *IFNL3* gene, notably rs12979860. are strongly associated with spontaneous and treatment-induced clearance of HCV, making it a key biomarker in predicting therapeutic outcomes.
Antibodies targeting IFNL3 or its receptor have been developed to study its biological functions and therapeutic potential. In research, anti-IFNL3 antibodies are used to block its activity, helping elucidate its role in immune regulation, viral persistence, and inflammatory diseases. Clinically, IFNL3 has been explored as a therapeutic target, particularly in chronic hepatitis and autoimmune conditions. For example, neutralizing antibodies could modulate excessive interferon signaling linked to tissue damage, while agonist antibodies might enhance antiviral responses. However, challenges remain, including understanding tissue-specific effects and managing interindividual variability due to genetic factors. IFNL3 antibodies thus represent a dual tool for dissecting immune mechanisms and developing targeted therapies in virology and immunology.
×
